Method for generation of broadly neutralizing anti-pathogen antibodies
Methods and composition for potentiating germinal centers are disclosed herein. The methods include potentiating germinal centers to enhance antibody production in response to a vaccine, to increase antibody titer in response to a vaccine, and to enhance B cell class switching.
1. A method for enhancing an immune response in a subject, comprising:
administering, after vaccination of the subject, one or more immune enhancers, wherein the immune enhancers are A2a adenosine receptor agonists,
and further comprising administering one or more additional immune enhancers selected from the group consisting of: ibudilast, mesembrine, rolipram, piclamilast, luteolin, drotaverine, and roflumilast.
2. The method of claim 1 , wherein enhancing the immune response comprises enhancing the production of high affinity, broadly neutralizing antibodies.
3. The method of claim 1 , wherein the A2a adenosine receptor agonist is one or more A2a adenosine receptor agonist selected from the group consisting of:
CGS21680, ATL146e, YT-146, Regadenozone, and UK42,097.
4. The method of claim 1 , wherein one or more of the immune enhancers are administered simultaneously with a vaccine during vaccination.
5. The method of claim 1 , wherein the one or more one immune enhancers are administered about 3 to 10 days after vaccination.
6. The method of claim 1 , wherein the one or more one immune enhancers are administered daily for about 3 to 42 days after vaccination.
7. The method of claim 1 , wherein administration of the immune enhancer increases the nitroiodophenyl (NIP)-5/25 ratio above 0.3.
8. A method for potentiating a germinal center and/or cells within the germinal center in a subject, the method comprising: administering after vaccination of the subject, one or more immune enhancers, wherein the immune enhancers are A2a adenosine receptor agonists,
and further comprising administering one or more additional immune enhancers selected from the group consisting of: ibudilast, mesembrine, rolipram, piclamilast, luteolin, drotaverine, and roflumilast.
9. The method of claim 8 , wherein potentiating the germinal center and/or cells within the germinal center induces the development of high affinity, broadly neutralizing antibodies.
10. The method of claim 8 , wherein potentiating the germinal center and/or cells within the germinal center comprises one or more of inducing a hypoxic environment and stimulating A2a and/or A2b adenosine receptors.
11. The method of claim 8 , wherein the A2a adenosine receptor agonist is one or more A2a adenosine receptor agonist selected from the group consisting of:
CGS21680, ATL146e, YT-146, Regadenozone, and UK42,097.